Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
about
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapyAdoptive cell transfer: a clinical path to effective cancer immunotherapyTargeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Adoptive T-Cell ImmunotherapyUnderstanding the interplay between host immunity and Epstein-Barr virus in NPC patientsT lymphocytes targeting native receptorsEmerging treatment options for nasopharyngeal carcinomaCellular immunotherapy for pediatric solid tumorsTherapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaNovel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccineMetronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cellsHumoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls.The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersImmunotherapy of human cancers using gene modified T lymphocytes.Immunotherapeutic Intervention against Sarcomas.Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation.Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.Clinical outcome of HIV viraemic controllers and noncontrollers with normal CD4 counts is exclusively determined by antigen-specific CD8+ T-cell-mediated HIV suppressionOptimizing the production of suspension cells using the G-Rex "M" series.Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAUT cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo.Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disordersA phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.Genetically modified T-cell therapy for osteosarcomaAn overview of viral oncology in Italy - report from the Pavia meeting on solid tumors.Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive TumorsImmunotherapies for Hodgkin's lymphoma.Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma.Exploiting the curative potential of adoptive T-cell therapy for cancer.Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers.
P2860
Q24596055-ACCB8583-E675-4EF5-A060-FC77ED10A603Q24644774-92339069-F658-46E9-AE60-2C38DBA918F4Q26765429-262EB1BF-1E99-4E60-9128-4EFD5091EC38Q26782845-979F2C84-AEF7-42C5-B3F4-82292069C47FQ26823898-7ACE07B3-E321-4A41-A45F-44B74F9F3647Q26853345-0B016FDC-192A-42AD-B85F-EF1257AEE5EEQ26995560-D246FAA6-CB3B-47A2-B66F-96D244C2967EQ27014912-96B7D0B7-24BC-4420-9535-9E853D23D32EQ27016002-4D54C573-FA0B-45DE-86AA-B0E9BADD7D47Q28749468-43C90D93-E46C-4CEA-BBDF-B5D10E26E5D0Q30846827-4F9B9090-82A7-4C41-A09A-F760E0621961Q33806895-815BA02A-7AA8-4084-A3FD-8E155E33FE1EQ33822681-9E17743F-CBF2-45FA-AE26-1EDDC0FB2AD9Q34166602-4EBC874B-1FCD-4AB7-84FC-841CE9D3BD79Q34188383-8B2380AD-31B3-4183-B4E1-F813C4CC9A4CQ34196481-F730D777-0AC7-4ABF-9A73-6EE4C30CFF59Q34242449-967D8D3A-4183-44A0-8291-970D1BD72167Q34771143-4729D5D9-4F49-4639-8C8B-E7DA60D301AFQ35005421-9DFA8C8A-7D5F-4FD8-A3C0-6D2FE5B5A336Q35121627-31D7EC4C-EAB5-4CD9-A022-77AD708B6B96Q35170658-B785AA73-1500-4D82-8AF5-6CD36CA76A34Q35184232-DFFA213A-5144-4220-8A77-60D002839D7EQ35226501-CC76608A-5BF5-4DAB-A07B-DFFE8CA84ECEQ35483599-62055A43-2364-42E5-B898-791A5E314336Q35507358-17B0998A-EDF1-4CA5-8D02-6A85822CC2DCQ35670921-E975F7A3-1B0A-4665-A8E8-A40048DEA884Q35684896-8B1BA9A9-9C6C-4E4E-835B-104A3E32A0BAQ35738744-459CFB3C-B9B7-4FA9-A429-822FCE6D6F62Q35857642-34DE3946-7856-47F4-885F-FAD73B2E2CB4Q36059585-931DC848-36F7-4D58-97FE-DF1101C4F93FQ36198232-323E95CB-66A1-4BA2-9440-00060AB9E093Q36468756-BF8B1A3B-FFFE-4B6E-B556-D14AE444B6BDQ36807231-ADFF2359-0D10-42D0-81A4-F5C67F06E17FQ37006427-6124A677-9EBD-41BD-BC1F-6B1BDB52A5C4Q37129671-72608672-989F-4D24-935A-003C664BB3EEQ37171008-1D4EAB8E-E71E-47FB-8650-4B9BBC5499F0Q37545032-5C106052-4901-4EFF-8F12-D62CEFFFDA59Q37576033-E636888F-13F4-4AEB-A4DB-2CA71D34DAC7Q37585288-E07DA125-6BF1-4700-9632-14ED4636E766Q37622152-79AB0FBE-9DF3-4EE9-89FE-6C56EDE39BFF
P2860
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cell therapy of stage IV nasop ...... geted cytotoxic T lymphocytes.
@en
Cell therapy of stage IV nasop ...... geted cytotoxic T lymphocytes.
@nl
type
label
Cell therapy of stage IV nasop ...... geted cytotoxic T lymphocytes.
@en
Cell therapy of stage IV nasop ...... geted cytotoxic T lymphocytes.
@nl
prefLabel
Cell therapy of stage IV nasop ...... geted cytotoxic T lymphocytes.
@en
Cell therapy of stage IV nasop ...... geted cytotoxic T lymphocytes.
@nl
P2093
P50
P356
P1476
Cell therapy of stage IV nasop ...... rgeted cytotoxic T lymphocytes
@en
P2093
Cesare Perotti
Chiara Frasson
Franco Locatelli
Massimo Labirio
Mauro Moroni
Ornella Carminati
Patrizia Comoli
Rita Maccario
Roberta Schiavo
Simona Secondino
P304
P356
10.1200/JCO.2005.02.6195
P407
P577
2005-10-03T00:00:00Z